Fhit deficiency-induced global genome instability promotes mutation and clonal expansion

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Miuma, Satoshi ^a,b   Saldivar, Joshua C ^a,c   Karras, Jenna R ^a   Waters, Catherine E ^a   Paisie, Carolyn A ^a   Wang, Yao ^a   Jin, Victor ^a   Sun, Jin ^a   Druck, Teresa ^a   Zhang, Jie ^a   Huebner, Kay ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b NAGASAKI UNIVERSITY   (Japan)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID ANHYDRIDE HYDROLASE; CASPASE 3; FRAGILE HISTIDINE TRIAD PROTEIN; MCL1 PROTEIN, MOUSE; MYELOID LEUKEMIA FACTOR 1; PROTEIN P53; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; TUMOR PROTEIN;

ANIMAL; CELL LINE; DEFICIENCY; FIBROBLAST; GENETICS; GENOMIC INSTABILITY; HETEROZYGOSITY LOSS; KIDNEY; METABOLISM; MOUSE; MUTATION; PHYSIOLOGY;

ACID ANHYDRIDE HYDROLASES; ANIMALS; CASPASE 3; CELL LINE; FIBROBLASTS; GENOMIC INSTABILITY; KIDNEY; LOSS OF HETEROZYGOSITY; MICE; MUTATION; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NEOPLASM PROTEINS; RHO GTP-BINDING PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84893557882     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080730     Document Type: Article

References (36)

1. Negrini S, Gorgoulis VG, Halazonetis TD (2010) Genomic instability - an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11: 220-228. doi: 10.1038/nrm2858. PubMed: 20177397.
2. Arlt MF, Durkin SG, Ragland RL, Glover TW (2006) Common fragile sites as targets for chromosome rearrangements. DNA Repair 5: 1126-1135. doi:10.1016/j.dnarep.2006.05.010. PubMed: 16807141. (Pubitemid 44376448)
3. Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F et al. (1998) Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 58: 5032-5037. PubMed: 9823304. (Pubitemid 28521154)
4. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A et al. (2005) Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434: 907-913. doi: 10.1038/nature03485. PubMed: 15829965. (Pubitemid 40559004)
5. Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F et al. (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864-870. doi:10.1038/nature03482. PubMed: 15829956. (Pubitemid 40558993)
6. Bignell GR, Greenman CD, Davies H, Butler AP, Edkins S et al. (2010) Signatures of mutation and selection in the cancer genome. Nature 463: 893-898. doi:10.1038/nature08768. PubMed: 20164919.
7. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R et al. (1996) The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84: 587-597. doi:10.1016/S0092-8674(00)81034-X. PubMed: 8598045. (Pubitemid 26071739)
8. Letessier A, Millot GA, Koundrioukoff S, Lachagès AM, Vogt N et al. (2011) Cell-type-specific replication initiation programs set fragility of the FRA3B fragile site. Nature 470: 120-123. doi:10.1038/nature09745. PubMed: 21258320.
9. Pichiorri F, Palumbo T, Suh SS, Okamura H, Trapasso F et al. (2008) Fhit tumor suppressor: guardian of the preneoplastic genome. Future Oncol 4: 815-824. Review. doi:10.2217/14796694.4.6.815. PubMed: 19086848.
10. Zanesi N, Fidanza V, Fong LY, Mancini R, Druck T et al. (2001) The tumor spectrum in Fhit-deficient mice. Proc Natl Acad Sci U-S-A 981: 10250-10255. PubMed: 11517343.
11. Fong LY, Fidanza V, Zanesi N, Lock LF, Siracusa LD et al. (2000) Muir- Torre-like syndrome in Fhit-deficient mice. Proc Natl Acad Sci U S A 97: 4742-4747. doi:10.1073/pnas.080063497. PubMed: 10758156. (Pubitemid 30238628)
12. Ishii H, Zanesi N, Vecchione A, Trapasso F, Yendamuri S et al. (2003) Regulation of upper gastric cancer in mice by Fhit gene delivery. FASEB J 17: 1768-1770. PubMed: 12958204.
13. Saldivar JC, Shibata H, Huebner K (2010) Pathology and biology associated with the fragile FHIT gene and gene product. J Cell Biochem 109: 858-865. Review. PubMed: 20082323.
14. Saldivar JC, Miuma S, Bene J, Hosseini SA, Shibata H et al. (2012) Initiation of genome instability and preneoplastic processes through loss of Fhit expression. PLOS Genet 8: e1003077. PubMed: 23209436.
15. Hachiya N, Yajima N, Hatakeyama S, Yuno K, Okada N et al. (1999) Induction of lacZ mutation by 7,12-dimethylbenz[a]anthracene in various tissues of transgenic mice. Mutat Res 444: 283-295. doi: 10.1016/S1383-5718(99)00063-7. PubMed: 10521669. (Pubitemid 29469473)
16. Yang H, Ding Y, Hutchins LN, Szatkiewicz J, Bell TA et al. (2009) A customized and versatile high-density genotyping array for the mouse. Nat Methods 6: 663-666. doi:10.1038/nmeth.1359. PubMed: 19668205.
17. Djalali M, Adolph S, Steinbach P, Winking H, Hameister H (1987) A comparative mapping study of fragile sites in the human and murine genomes. Hum Genet 77: 157-162. doi:10.1007/BF00272384. PubMed: 3653889. (Pubitemid 17160061)
18. Hosseini SA, Saldivar JC, Miuma S, Horton S, Heerema NA, Huebner K (, Aug 92013) Chromosome fragile sites in cells of epithelial origin, with and without Fhit expression. Genes Chrom Cancer, Aug 9. doi: 10.1002/gcc.22097.
19. Litaker JR, Pan J, Cheung Y, Zhang DK, Liu Y et al. (1998) Expression profile of senescence-associated beta-galactosidase and activation of telomerase in human ovarian surface epithelial cells undergoing immortalization. Int J Oncol 13: 951-956. PubMed: 9772284.
20. Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245. doi: 10.1016/0092-8674(92)90644-R. PubMed: 1535557.
21. Wheatley SP, McNeish IA (2005) Survivin: a protein with dual roles in mitosis and apoptosis. Int Rev Cytol 247: 35-88. Review. doi:10.1016/S0074- 7696(05)47002-3. PubMed: 16344111.
22. Stephenson-Famy A, Marks J, Suresh A, Caritis SN, Simhan H et al. (2012) Antiapoptotic signaling via MCL1 confers resistance to caspase-3-mediated apoptotic cell death in the pregnant human uterine myocyte. Mol Endocrinol 26: 320-330. doi:10.1210/me.2011-1282. PubMed: 22194343.
23. Weinberg WC, Denning MF (2002) P21Waf1 control of epithelial cell cycle and cell fate. Crit Rev Oral Biol Med 13: 453-464. Review. doi: 10.1177/154411130201300603. PubMed: 12499239.
24. Sard L, Accornero P, Tornielli S, Delia D, Bunone G et al. (1999) The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci U S A 96: 8489-8492. doi: 10.1073/pnas.96.15.8489. PubMed: 10411902. (Pubitemid 29354818)
25. Suzuki T, Itoh S, Nakajima M, Hachiya N, Hara T (1999) Target organ and time-course in the mutagenicity of five carcinogens in MutaMouse: a summary report of the second collaborative study of the transgenic mouse mutation assay by JEMS/MMS. Mutat Res 444: 259-268. doi: 10.1016/S1383-5718(99)00104-7. PubMed: 10521667. (Pubitemid 29469471)
26. Moolmuang B, Tainsky MA (2011) CREG1 enhances p16(INK4a)-induced cellular senescence. Cell Cycle 10: 518-530. doi:10.4161/cc. 10.3.14756. PubMed: 21263217.
27. Boudreau HE, Casterline BW, Rada B, Korzeniowska A, Leto TL (2012) Nox4 involvement in TGF-beta and SMAD3-driven induction of the epithelial-to- mesenchymal transition and migration of breast epithelial cells. Free Radic Biol Med 53: 1489-1499. doi:10.1016/j.freeradbiomed.2012.06.016. PubMed: 22728268.
28. Weyemi U, Dupuy C (2012) The emerging role of ROS-generating NADPH oxidase NOX4 in DNA-damage responses. Mutat Res 751: 77-81. doi:10.1016/j.mrrev. 2012.04.002. PubMed: 22580379.
29. Merikallio H, Kaarteenaho R, Pääkkö P, Lehtonen S, Hirvikoski P et al. (2003) Early growth response 1 protein, an upstream gatekeeper of the p53 tumor suppressor, controls replicative senescence. Proc Natl Acad Sci U S A 100: 3233-3238. doi:10.1073/pnas.2628034100. PubMed: 12629205.
30. Yoshihara Y, Wu D, Kubo N, Sang M, Nakagawara A, Ozaki T (2012) Inhibitory role of E2F-1 in the regulation of tumor suppressor p53 during DNA damage response. Biochem Biophys Res Commun 421: 57-63. doi:10.1016/j.bbrc.2012. 03.108. PubMed: 22480684.
31. Jackson MW, Agarwal MK, Yang J, Bruss P, Uchiumi T et al. (2005) p130/p107/p105Rb-dependent transcriptional repression during DNA-damage-induced cell-cycle exit at G2. J Cell Sci 118: 1821-1832. doi: 10.1242/jcs.02307. PubMed: 15827088. (Pubitemid 40723827)
32. Zhu L, Harlow E, Dynlacht BD (1995) p107 uses a p21CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F. Genes Dev 9: 1740-1752. doi:10.1101/gad.9.14.1740. PubMed: 7622038.
33. Hollander MC, Kovalsky O, Salvador JM, Kim KE, Patterson AD et al. (2001) Dimethylbenzanthracene carcinogenesis in Gadd45a-null mice is associated with decreased DNA repair and increased mutation frequency. Cancer Res 61: 2487-2491. PubMed: 11289119. (Pubitemid 32685828)
34. Taylor BJ, Nik-Zainal S, Wu YL, Stebbings LA, Raine K et al. (2013) DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. Elife 2: e00534. doi:10.7554/eLife.00534. PubMed: 23599896.
35. Roberts SA, Lawrence MS, Klimczak LK et al. (2013) An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 45: 970-976. doi:10.1038/ng.2702. PubMed: 23852170.
36. Becker K, Goldberg M, Helmbold P, Holbach LM, Loeffler KU, Ballhausen WG (2008) Deletions of BRCA1/2 and p53 R248W gain-of-function mutation suggest impaired homologous recombination repair in fragile histidine triad-negative sebaceous gland carcinomas. Br J Dermatol 159: 1282-1289. doi:10.1111/j.1365- 2133.2008.08783.x. PubMed: 18717684.